◆英語タイトル:Immunicum AB (IMMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013446
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Immunicum AB (Immunicum) is a biopharmaceutical company that develops immuno-oncology therapies for the treatment of solid tumors. The company’s products include COMBIG, CD70, SUBCUVAX and adenovirusvector. Its SUBCUVAX is in preclinical trials in combination with the adenovirus vector for the treatment of cancer; CD70-platform, which is in a preclinical phase study that facilitates the development of adoptive immunotherapy drugs for the treatment of various types of solid tumors; and adenovirus vector, which is in preclinical study on cancer stem cells. The company uses therapeutic vaccines to treat an already existing disease; therapeutic cancer vaccines administered to patients in order to delay or stop tumor cell growth, shrink tumors, prevent relapse, and to kill cancer cells that could not be eliminated with other treatments. Immunicum is headquartered in Gothenburg, Sweden.
Immunicum AB (IMMU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Immunicum AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 10
Venture Financing 11
Immunicum Secures US$3.6 Million In Financing 11
Partnerships 12
Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 12
Equity Offering 13
Immunicum to Raise USD26.6 Million in Rights Offering of Shares 13
Immunicum Raises USD15.5 Million in Right Offering of Shares 15
Immunicum Completes IPO 17
Immunicum Announces Private Placement Of Shares For US$1.3 Million 18
Immunicum AB – Key Competitors 19
Immunicum AB – Key Employees 20
Immunicum AB – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Nov 17, 2017: Immunicum Interim Report Q3-Corporate Update and Outlook 22
Aug 18, 2017: Immunicum: Interim Report Q2 – Corporate Update and Outlook 24
May 19, 2017: Immunicum: Quarterly Report January-March 2017 26
Feb 17, 2017: Immunicum: Year-End Report 2016 (July 2016 – December 2016) 28
Corporate Communications 31
Sep 27, 2016: Immunicum Announces Carlos de Sousa as New CEO to take the Company to its Next Stage of Development 31
May 02, 2016: Immunicum applies for listing on the Nasdaq Stockholm main market 32
Product News 33
11/14/2016: Immunicum Presented Poster at SITC Conference on INTUVAX HCC I/II clinical study-Announces Last Patient Included in Study Extension 33
06/12/2017: Immunicum Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX 34
Product Approvals 35
Jul 22, 2016: Immunicum Submits IND Application To The Food And Drug Administration For Approval To Treat Kidney Cancer Patients In The United States In Its Ongoing Phase II-Trial 35
Clinical Trials 36
Feb 14, 2017: Immunicum announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma 36
Jun 23, 2016: Immunicum Announces Preliminary Plans to Initiate Clinical Trials with INTUVAX in Melanoma in both Sweden and the U.S. 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Tables
Immunicum AB, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immunicum AB, Deals By Therapy Area, 2011 to YTD 2017 8
Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 10
Immunicum Secures US$3.6 Million In Financing 11
Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 12
Immunicum to Raise USD26.6 Million in Rights Offering of Shares 13
Immunicum Raises USD15.5 Million in Right Offering of Shares 15
Immunicum Completes IPO 17
Immunicum Announces Private Placement Of Shares For US$1.3 Million 18
Immunicum AB, Key Competitors 19
Immunicum AB, Key Employees 20